The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Content

• The CNS Market Outlook to 2013
• Executive Summary
• Overview and epidemiology of CNS disorders
• Global market analysis
• Pipeline analysis
• Competitive landscape
• Chapter 1 Scope and methodology
  • Scope
  • Methodology
• Chapter 2 Overview and epidemiology of
  • CNS disorders
  • Summary
  • Introduction
  • Schizophrenia
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • Major depressive disorder
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • Epilepsy
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • Alzheimers disease
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • iv
  • Insomnia
  • Overview
  • Epidemiology
  • Epidemiology
  • Parkinsons disease
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • Migraine
  • Overview
  • Epidemiology
  • Forecast epidemiology
  • Attention-deficit hyperactivity disorder
  • Overview
  • Epidemiology
• Chapter 3 Global market analysis
  • Summary
  • Introduction
  • Market analysis by country
  • Licensing trends
  • Market analysis by indication
  • Leading brand dynamics
  • Key events in the CNS disorder market
  • Launch of first transdermal patch formulation of Novartis Exelon
  • for the treatment of AD
  • Once-Daily and long acting stimulants remain the gold standard in
  • the treatment of ADHD
  • Disappointing clinical results from bapineuzumab
  • Recall of Neupro in the US due to manufacturing problems
  • Spheramine fails to demonstrate efficacy in Phase IIb Parkinson's
  • disease study
  • GLP-1 may treat Parkinsons disease
  • Acetyl cholinesterase inhibitors to remain the mainstay treatment
  • option for AD
  • Newer therapies in epilepsy prove efficacious in multiple CNS
  • disorder indications
  • FDA orders warning labels for antipsychotic drugs
  • Newer agents continue to dominate antipsychotic market
  • Label expansions for SSRIs provides an opportunity for growth and
  • differentiation
  • Schizophrenia
  • Market analysis
  • Leading brands in the schizophrenia market
  • v
  • Atypical antipsychotics
  • Key brand analysis
  • Schizophrenia sales forecast to 2013
  • Major depressive disorder (MDD)
  • Market analysis
  • Leading brands in the antidepressants market
  • Selective Serotonin Reuptake inhibitors
  • Market Dynamics
  • Key brand analysis
  • Selective Norepinephrine Reuptake Inhibitors
  • Market Dynamics
  • Key brand analysis
  • Antidepressants sales forecast to 2013
  • Epilepsy
  • Market analysis
  • Leading brands in the anti-epileptic market
  • Second generation anti-epileptics
  • Key brand analysis
  • Anti-epilepsy sales forecast to 2013
  • Alzheimers disease
  • Market analysis
  • Leading brands in the anti-Alzheimers market
  • Cholinesterase inhibitors market analysis
  • Market analysis
  • Key brand analysis
  • NMDA receptor antagonists market analysis
  • Key brand analysis
  • Anti-Alzheimers sales forecast to 2013
  • Insomnia
  • Market analysis
  • Non-benzodiazepines
  • Key brand analysis
  • Anti-insomnia sales forecast to 2013
  • Parkinsons disease (PD)
  • Market analysis
  • Leading brands in the anti-parkinsons market
  • COMT inhibitors
  • Key brand analysis
  • Dopamine agonists
  • Key brand analysis
  • Mono-amino oxidase (MAO) inhibitors
  • Key brand analysis
  • Anti-parkinsons sales forecast to 2013
  • Migraine
  • Market analysis
  • Leading brands in the anti-migraine market
  • Triptans
  • Key brand analysis
  • Anti-migraine sales forecast to 2013
  • vi
  • Attention-deficit hyperactivity disorder (ADHD)
  • Market analysis
  • Leading brands in the ADHD market
  • Stimulants
  • Key brand analysis
  • Non-stimulants
  • Key brand analysis
  • ADHD sales forecast to 2013
  • Total CNS disorders sales forecast
• Chapter 4 Pipeline analysis
  • Summary
  • Introduction
  • Key trends in R & D
  • Disease modifying agents hold promise in AD
  • Novel drugs with differentiated profiles represent a sizeable market
  • opportunity
  • New drug delivery formulations confer a competitive advantage
  • Combination drugs demonstrate advantages over individual components
  • CNS disorders pipeline
  • Leading drugs in development
  • Profiles of key pipeline products
  • Recently marketed drugs
  • Invega
  • Pristiq
  • Treximet
  • Vyvanse
  • Drugs in registration
  • Asenapine
  • Inovelon
  • Paliperidone Palmitate
  • Vimpat
  • Drugs in phase III clinical studies
  • Almorexant (ACT-078573)
  • Amibegron (SR-58611)
  • Bapineuzumab (AAB-001)
  • Eplivanserin (SR-46349)
  • Saredutant (SR-48968)
  • Semagacestat (LY-450139)
  • Telcagepant (MK-0974)
  • Pipeline forecast
  • vii
• Chapter 5 Competitive landscape
  • Summary
  • Introduction
  • Sales performance of leading players
  • Detailed analysis of leading CNS players
  • Johnson & Johnson (J&J)
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Eli Lilly
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • Marketed product portfolio: Strattera
  • R&D pipeline analysis
  • Strategic and growth analysis
  • GlaxoSmithKline (GSK)
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Pfizer
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • AstraZeneca
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Novartis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sanofi-Aventis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • viii
  • Wyeth
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Forest
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Eisai
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Chapter 6 Appendix
  • IMS Data
  • N2C - Anti-Migraine preparations
  • N3A Anti-Epileptics
  • N4A Anti-Parkinson drugs
  • N5A Antipsychotics
  • N5B Hypnotics/Sedatives
  • N6A Antidepressants
  • N6B - Psychostimulants
  • N7D - Anti-Alzheimers products
  • N7X Other CNS drugs
  • Glossary
  • AD Assessment Scale cognition; (ADAS-cog)
  • ADHD-RS
  • Clinical Dementia Rating (CDR) scale
  • HAM-D17
  • Mini Mental State Exam (MMSE)
  • Neuropsychological Test Battery (NTB)
  • Personal and Social Performance Scale (PSP)
  • Positive and Negative Syndrome Scale for schizophrenia (PANSS)
• List of Figures
  • Figure 2.1: Schizophrenia: classification of symptoms
  • Figure 2.2: Typical treatment patterns in the treatment of schizophrenia
• ix
  • Figure 2.3: Different forms of epilepsy
  • Figure 2.4: Different stages of Alzheimers disease
  • Figure 2.5: Typical treatment patterns in the treatment of Alzheimers disease
  • Figure 2.6: Typical treatment patterns in the treatment of migraine
  • Figure 3.7: Global CNS market share by geography, 2007
  • Figure 3.8: Sales of types of CNS disorder brands, 20062007
  • Figure 4.9: Key trends in the R&D of CNS disorders, 2008
  • Figure 4.10: Leading recently launched products and late-stage R&D compounds indicated for the
• treatment of CNS disorders, 2008
  • Figure 5.11: Market share of key players by sales value, 2007
  • Figure 5.12: Projected market share of key players by sales value, 2013
  • Figure 5.13: Market share and ranking of leading players in the global CNS disorders market,
• 20072013
  • Figure 5.14: J&Js CNS portfolio sales by indication, 2007
  • Figure 5.15: Eli Lillys CNS portfolio sales by indication, 2007
  • Figure 5.16: GSKs CNS portfolio sales by indication, 2007
  • Figure 5.17: Pfizers CNS portfolio sales by indication, 2007
  • Figure 5.18: AstraZenecas portfolio sales by indication, 2007
  • Figure 5.19: Novartis portfolio sales by indication, 2007
  • Figure 5.20: Sanofi-Aventis portfolio sales by indication, 2007
  • Figure 5.21: Wyeths portfolio sales by indication, 2007
  • Figure 5.22: Forests portfolio sales by indication, 2007
  • Figure 5.23: Eisais portfolio sales by indication, 2007
• x
  • Table 2.1: Estimated prevalence of CNS disorders across the seven major
  • Table 2.2: Estimated prevalence of schizophrenia across the seven major markets, 2007
  • Table 2.3: Forecast epidemiology of schizophrenia across the seven major markets, 20072013
  • Table 2.4: Estimated prevalence of MDD across the seven major markets, 2007
  • Table 2.5: Estimated prevalence of MDD across the seven major markets, 2007
  • Table 2.6: Estimated prevalence of epilepsy across the seven major markets, 2007
  • Table 2.7: Forecast epidemiology of epilepsy across the seven major markets, 20072013
  • Table 2.8: Estimated prevalence of Alzheimer's disease across the seven major markets, 2007
  • Table 2.9: Forecast epidemiology of AD across the seven major markets, 20072013
  • Table 2.10: Estimated prevalence of insomnia across the seven major markets, 2007
  • Table 2.11: Estimated prevalence of Parkinson's disease across the seven major markets, 2007
  • Table 2.12: Estimated prevalence of Parkinson's disease across the seven major markets, 2007
  • Table 2.13: Estimated prevalence of migraine across the seven major markets, 2007
  • Table 2.14: Forecast epidemiology of migraine across the seven major markets, 20072013
  • Table 2.15: Estimated prevalence of ADHD in adults across the seven major markets, 2008
  • Table 2.16: Estimated prevalence of ADHD in children across the seven major markets, 2008
  • Table 3.17: Breakdown of the global CNS market by drug class, $m, 20062007
  • Table 3.18: Leading brands in the global CNS market, $m, 20062007
  • Table 3.19: Breakdown of the global schizophrenia market by drug class, $m, 20062007
  • Table 3.20: Leading antipsychotic medications in the CNS market, $m, 20062007
  • Table 3.21: Antipsychotic products sales forecast, $m, 20072013
  • Table 3.22: Breakdown of the global antidepressant market by drug class, $m, 20062007
  • Table 3.23: Leading antipsychotic medications in the CNS market, $m, 20062007
  • Table 3.24: Leading SSRIs in the MDD market, $m, 20062007
  • Table 3.25: Leading SNRIs in the MDD market, $m, 20062007
  • Table 3.26: Antidepressants sales forecast, $m, 20072013
  • Table 3.27: Global epilepsy market, $m, 20062007
  • Table 3.28: Leading anti-epileptic medications in the CNS market, $m, 20062007
  • Table 3.29: Anti-epileptics sales forecast, $m, 20072013
  • Table 3.30: Breakdown of the global anti-alzheimers market by drug class, $m, 20062007
  • Table 3.31: Leading anti-alzheimer drugs in the global CNS market by drug class, $m, 20062007
  • Table 3.32: Leading cholinesterase inhibitors in the global anti-alzheimers market by drug class,
• $m, 20062007
  • Table 3.33: Leading NMDA receptor antagonists in the global anti-alzheimers market by drug
• class, $m, 20062007
  • Table 3.34: Anti-alzheimer's products sales forecast, $m, 20072013
  • Table 3.35: Breakdown of the global insomnia market by drug class, $m, 20062007
  • Table 3.36: Leading insomnia drugs in the global CNS market by drug class, $m, 20062007
  • Table 3.37: Anti-insomnia products sales forecast, $m, 20072013
  • Table 3.38: Global anti-parkinsons disease market, $m, 20062007
  • Table 3.39: Leading anti-parkinson drugs in the global CNS market by drug class, $m, 20062007
  • Table 3.40: Anti-parkinson drugs sales forecast, $m, 20072013
  • Table 3.41: Breakdown of the global anti-migraine market by drug class, $m, 20062007
  • Table 3.42: Leading anti-migraine medications in the CNS market, $m, 20062007
• xi
  • Table 3.43: Anti-migraine products sales forecast, $m, 20072013
  • Table 3.44: Breakdown of the global ADHD market by drug class, $m, 20062007
  • Table 3.45: Leading ADHD medications in the CNS market, $m, 20062007
  • Table 3.46: Anti-ADHD products sales forecast, $m, 20072013
  • Table 3.47: CNS Market sales forecast by drug class, $m, 20072013
  • Table 4.48: CNS pipeline by indication and stage of development, 1H2008
  • Table 4.49: An overview of Invega
  • Table 4.50: An overview of Pristiq
  • Table 4.51: An overview of Treximet
  • Table 4.52: An overview of Vyvanse
  • Table 4.53: An overview of Asenapine
  • Table 4.54: An overview of Inovelon
  • Table 4.55: An overview of Paliperidone Palmitate
  • Table 4.56: An overview of Vimpat
  • Table 4.57: An overview of Almorexant (ACT-078573)
  • Table 4.58: An overview of Amibegron (SR-58611)
  • Table 4.59: An overview of Bapineuzumab (AAB-001)
  • Table 4.60: An overview of Eplivanserin (SR-46349)
  • Table 4.61: An overview of Saredutant (SR-48968)
  • Table 4.62: An overview of Semagacestat (LY-450139)
  • Table 4.63: An overview of Telcagepant (MK-0974)
  • Table 4.64: CNS disorders pipeline forecast, 20082013 ($m)
  • Table 5.65: Leading players in the global CNS disorders market, 20072013 ($m)
  • Table 5.66: J&Js CNS product portfolio, 20062007
  • Table 5.67: J&Js CNS R&D product pipeline, 2007
  • Table 5.68: Eli Lillys CNS product portfolio, 20062007
  • Table 5.69: Eli Lilly's CNS R&D product pipeline, 2007
  • Table 5.70: GSKs CNS product portfolio, 20062007
  • Table 5.71: GSK's CNS R&D product pipeline, 2007
  • Table 5.72: Pfizers CNS product portfolio, 20062007
  • Table 5.73: Pfizer's CNS R&D product pipeline, 2007
  • Table 5.74: AstraZenecas CNS product portfolio, 20062007
  • Table 5.75: AstraZeneca's CNS R&D product pipeline, 2007
  • Table 5.76: Novartis CNS product portfolio, 20062007
  • Table 5.77: Novartis' CNS R&D product pipeline, 2007
  • Table 5.78: Sanofi-Aventis CNS product portfolio, 20062007
  • Table 5.79: Sanofi-Aventis' CNS R&D product pipeline, 2007
  • Table 5.80: Wyeths CNS product portfolio, 20062007
  • Table 5.81: Wyeth's CNS R&D product pipeline, 2007
  • Table 5.82: Forests CNS product portfolio, 20062007
  • Table 5.83: Forests' CNS R&D product pipeline, 2007
  • Table 5.84: Eisais CNS product portfolio, 20062007
  • Table 5.85: Eisai's CNS R&D product pipeline, 2007